Cargando…
Two Approaches to Triple Antithrombotic Therapy in Patients with Acute Coronary Syndrome and Non-Valvular Atrial Fibrillation Treated with Percutaneous Coronary Intervention: Which Is More Efficient and Safer?
Introduction: Patients with acute coronary syndrome (ACS) and atrial fibrillation (AF) treated with percutaneous coronary intervention (PCI) are at high risk of bleeding and thromboembolic events. Thus, optimal treatment strategies in this challenging subset have been controversial. Herein, we aim t...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10572308/ https://www.ncbi.nlm.nih.gov/pubmed/37835798 http://dx.doi.org/10.3390/diagnostics13193055 |
_version_ | 1785120204615843840 |
---|---|
author | Bachorski, Witold Bychowski, Jakub Gruchała, Marcin Jaguszewski, Miłosz |
author_facet | Bachorski, Witold Bychowski, Jakub Gruchała, Marcin Jaguszewski, Miłosz |
author_sort | Bachorski, Witold |
collection | PubMed |
description | Introduction: Patients with acute coronary syndrome (ACS) and atrial fibrillation (AF) treated with percutaneous coronary intervention (PCI) are at high risk of bleeding and thromboembolic events. Thus, optimal treatment strategies in this challenging subset have been controversial. Herein, we aim to investigate different triple antithrombotic treatment (TAT) strategies in patients with ACS and AF after PCI. Methods: This was a retrospective, single-center study based on all consecutive patients with the diagnosis of ACS and AF treated with vitamin K antagonists (VKA) or non-vitamin K antagonist oral anticoagulants (NOAC) plus dual antiplatelet therapy using a P2Y12 inhibitor (clopidogrel) and aspirin (for 1 to 3 months) and observed for 12 months for major adverse cardiac events (MACE) and major or clinically relevant non-major bleeding incidents. Results: MACE occurred in 26.6% of patients treated with the VKA and 30.9% with NOAC (p = 0.659). Bleeding occurred in 7.8% of patients treated with VKA and 7.4% with NOAC (ns). Conclusions: Among patients with ACS and AF who had undergone PCI, there was no significant difference in the risk of bleeding and ischemic events among those who received TAT with NOAC and VKA. |
format | Online Article Text |
id | pubmed-10572308 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-105723082023-10-14 Two Approaches to Triple Antithrombotic Therapy in Patients with Acute Coronary Syndrome and Non-Valvular Atrial Fibrillation Treated with Percutaneous Coronary Intervention: Which Is More Efficient and Safer? Bachorski, Witold Bychowski, Jakub Gruchała, Marcin Jaguszewski, Miłosz Diagnostics (Basel) Brief Report Introduction: Patients with acute coronary syndrome (ACS) and atrial fibrillation (AF) treated with percutaneous coronary intervention (PCI) are at high risk of bleeding and thromboembolic events. Thus, optimal treatment strategies in this challenging subset have been controversial. Herein, we aim to investigate different triple antithrombotic treatment (TAT) strategies in patients with ACS and AF after PCI. Methods: This was a retrospective, single-center study based on all consecutive patients with the diagnosis of ACS and AF treated with vitamin K antagonists (VKA) or non-vitamin K antagonist oral anticoagulants (NOAC) plus dual antiplatelet therapy using a P2Y12 inhibitor (clopidogrel) and aspirin (for 1 to 3 months) and observed for 12 months for major adverse cardiac events (MACE) and major or clinically relevant non-major bleeding incidents. Results: MACE occurred in 26.6% of patients treated with the VKA and 30.9% with NOAC (p = 0.659). Bleeding occurred in 7.8% of patients treated with VKA and 7.4% with NOAC (ns). Conclusions: Among patients with ACS and AF who had undergone PCI, there was no significant difference in the risk of bleeding and ischemic events among those who received TAT with NOAC and VKA. MDPI 2023-09-26 /pmc/articles/PMC10572308/ /pubmed/37835798 http://dx.doi.org/10.3390/diagnostics13193055 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Brief Report Bachorski, Witold Bychowski, Jakub Gruchała, Marcin Jaguszewski, Miłosz Two Approaches to Triple Antithrombotic Therapy in Patients with Acute Coronary Syndrome and Non-Valvular Atrial Fibrillation Treated with Percutaneous Coronary Intervention: Which Is More Efficient and Safer? |
title | Two Approaches to Triple Antithrombotic Therapy in Patients with Acute Coronary Syndrome and Non-Valvular Atrial Fibrillation Treated with Percutaneous Coronary Intervention: Which Is More Efficient and Safer? |
title_full | Two Approaches to Triple Antithrombotic Therapy in Patients with Acute Coronary Syndrome and Non-Valvular Atrial Fibrillation Treated with Percutaneous Coronary Intervention: Which Is More Efficient and Safer? |
title_fullStr | Two Approaches to Triple Antithrombotic Therapy in Patients with Acute Coronary Syndrome and Non-Valvular Atrial Fibrillation Treated with Percutaneous Coronary Intervention: Which Is More Efficient and Safer? |
title_full_unstemmed | Two Approaches to Triple Antithrombotic Therapy in Patients with Acute Coronary Syndrome and Non-Valvular Atrial Fibrillation Treated with Percutaneous Coronary Intervention: Which Is More Efficient and Safer? |
title_short | Two Approaches to Triple Antithrombotic Therapy in Patients with Acute Coronary Syndrome and Non-Valvular Atrial Fibrillation Treated with Percutaneous Coronary Intervention: Which Is More Efficient and Safer? |
title_sort | two approaches to triple antithrombotic therapy in patients with acute coronary syndrome and non-valvular atrial fibrillation treated with percutaneous coronary intervention: which is more efficient and safer? |
topic | Brief Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10572308/ https://www.ncbi.nlm.nih.gov/pubmed/37835798 http://dx.doi.org/10.3390/diagnostics13193055 |
work_keys_str_mv | AT bachorskiwitold twoapproachestotripleantithrombotictherapyinpatientswithacutecoronarysyndromeandnonvalvularatrialfibrillationtreatedwithpercutaneouscoronaryinterventionwhichismoreefficientandsafer AT bychowskijakub twoapproachestotripleantithrombotictherapyinpatientswithacutecoronarysyndromeandnonvalvularatrialfibrillationtreatedwithpercutaneouscoronaryinterventionwhichismoreefficientandsafer AT gruchałamarcin twoapproachestotripleantithrombotictherapyinpatientswithacutecoronarysyndromeandnonvalvularatrialfibrillationtreatedwithpercutaneouscoronaryinterventionwhichismoreefficientandsafer AT jaguszewskimiłosz twoapproachestotripleantithrombotictherapyinpatientswithacutecoronarysyndromeandnonvalvularatrialfibrillationtreatedwithpercutaneouscoronaryinterventionwhichismoreefficientandsafer |